英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Stallman查看　Stallman　在百度字典中的解释百度英翻中〔查看〕
Stallman查看　Stallman　在Google字典中的解释Google英翻中〔查看〕
Stallman查看　Stallman　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have previously received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI
  • Regeneron’s Libtayo FDA Approved as First Immunotherapy to . . .
    The FDA has approved a new use of PD-1 inhibitor Libtayo (cemiplimab-rwlc) as a treatment for cutaneous squamous cell carcinoma (CSCC) that has a high risk of recurring after it has been treated with surgery and radiation The approval makes Libtayo the first immunotherapy approved for use after surgery and radiation and may change how patients are treated earlier in their disease As a PD-1
  • What is LIBTAYO® (cemiplimab-rwlc) | Advanced CSCC
    LIBTAYO is the first medicine approved by the Food and Drug Administration (FDA) to treat CSCC that has spread or cannot be cured by surgery or radiation LIBTAYO is a type of immunotherapy called a programmed death receptor-1 (PD-1) inhibitor LIBTAYO is not chemotherapy or radiation therapy LIBTAYO may be right for adults with a type of skin cancer called cutaneous squamous cell carcinoma
  • Libtayo® (cemiplimab) Approved in the European . . . - BioSpace
    Libtayo is also currently approved in the EU for the treatment of certain patients with advanced CSCC, advanced basal cell carcinoma (BCC), advanced non-small cell lung cancer (NSCLC) and recurrent or metastatic cervical cancer
  • Libtayo (cemiplimab-rwlc): Uses, Side Effects . . . - WebMD
    Libtayo (cemiplimab-rwlc) is commonly used to treat certain types of cancer It is used to treat certain types of skin cancers, including cutaneous squamous cell carcinoma (CSCC) and basal cell
  • US FDA expands use of Regenerons Libtayo as add-on treatment . . .
    The U S Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease
  • Libtayo: Side effects, how it works, cost, alternatives, and more
    Libtayo (cemiplimab-rwlc) is a brand-name injection that’s used for certain types of lung and skin cancer Learn about side effects and more
  • Cemiplimab-rwlc (Libtayo®) - OncoLink
    Skin reactions: Report rash, with or without itching (pruritis), sores in your mouth, blistering or peeling skin, as these can become severe and require treatment with corticosteroids Lung problems: (Pneumonitis, inflammation of the lung) New or worsening cough, shortness of breath, trouble breathing, or chest pain
  • Libtayo First PD-1 Inhibitor Treatment for . . . - CancerConnect
    The U S Food and Drug Administration (FDA) approved Libtayo (cemiplimab, REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma Cemiplimab is an investigational human, monoclonal antibody targeting PD-1





中文字典-英文字典  2005-2009